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Abstract: We report the case of a 19-year-old woman who received a complete vaccine program by Gardasil. After one year, Greiner 
HPV test revealed HPV51 positivity. This case report highlights the limits of the vaccine, and the need to have a clinical follow up of 
patients despite the vaccination program.
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Prophylactic vaccines targeting HPV6/11/16/18 and 
HPV16/18  infections  have  recently  been  shown 
to  reduce  the  incidence  of  cervical  intraepithelial 
neoplasia (CIN) due to these types.1,2 Because of its 
expected public health benefit on reduction of cervical 
cancer and other HPV-related diseases, this vaccine has 
been rapidly implemented in the routine vaccination 
programs of several countries. It is therefore essential 
to assess its impact and safety through post-licensure 
surveillance programs.3 Few data are available on the 
efficacy of Gardasil and Cervarix on non-HPV16 and 
non-HPV18  high-risk  types.4  Baseline  prevalence 
of HPV infection as well as the distribution of the 
different  HPV  types  in  the  population  and  among 
women with cervical lesions indicated that the five 
most prevalent HPV types without cytologic abnor-
malities were HPV16 (2.3%), HPV31 (2.1%), HPV51 
(1.6%), HPV53 (1.5%), and HPV59 (1.4%), whereas 
in high-grade squamous intraepithelial lesion (HSIL), 
the  most  prevalent  types  were  HPV16  (34.9%), 
HPV31 (23.9%), HPV39/HPV52 (both 12.8%), and 
HPV51 (11.9%).5
HPV51 is considered a high-risk HPV with a low 
prevalence  (0%–2.3%)  in  CIN  depending  on  the 
countries.6 Yet few data are available on the efficacy 
of Gardasil and Cervarix on this HPV 51 type; these 
two HPV commercially available vaccines probably 
do not protect against HPV51.
We report the case of a 19-year-old woman who 
received  a  complete  vaccine  program  by  Gardasil 
(HPV6/11/16/18 vaccine; Gardasil or Silgard; Merck 
and Co, Inc, Whitehouse Station, NJ) one year ago 
and was referred to her gynecologist for a routine 
pap  smear.  The  pap  smear  revealed  atypical  cells 
of undetermined significance (ASCUS), and a HPV 
high-risk detection test was found positive with high-
risk HPV51 (found twice at one month interval to 
avoid any sample mistake) using the Greiner HPV 
test and a GP5+GP6+ modified typing methodology.7 
This patient had no specific medical history, and no 
other sexually transmitted diseases, and she had two 
sexual partners during the year after the last injec-
tion  of  vaccine.  The  HBV  status  of  this  woman 
was  the  following:  HBs  antibody  titer,  5000  UI/L 
(consecutively to HBS vaccination as recommended 
by the French authorities), and the HBs antigen and 
HBc antibody were negative.
Guidelines for HPV vaccine do not recommend 
any HPV screening before vaccination. Indeed, due 
to the possibility that this woman already had HPV51 
at baseline, we cannot definitively establish whether 
this case is an incident case or a prevalent case.
It was reported that vaccination reduced the rate of 
HPV31/33/45/52/58 infection by 17.7% and of CIN1-3 
or adenocarcinoma in situ (AIS) by 18.8%.8 Vaccina-
tion  also  reduced  the  rate  of  HPV31/58/59-related 
CIN1-3/AIS by 26.0%, 28.1%, and 37.6%, respectively.9 
A slight reduction in HPV31/33/45/52/58-  related CIN2 
was observed, but it was not statistically   significant. 
This case report highlights the limits of the vaccine, 
specifically on non-HPV16 and non-HPV18, and the 
need to have a clinical follow up of patients despite the 
vaccination program. Also, determining the population-
based impact of HPV vaccines will require   longer-term 
surveillance,  beyond  the  vaccine  clinical  trial.  The 
clinical  benefit  of  cross-protection  is  not  expected 
to be fully additive to the efficacy already observed 
against HPV6/11/16/18-related disease. New vaccines 
are needed to address the problem of non-HPV16 and 
non-HPV18 high-risk types for which Gardasil has no 
protective effect.
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